BEBT-908 (BEBT908, CUDC-908) is a novel potent, dual PI3K/HDAC inhibitor with nanomolar IC50 values of <0.1 uM (PI3Kα) and 0.1-1 uM (HDAC).
BEBT-908 inhibited multiple pathways, including JAK/STAT3, MAPK/ERK and NF-κB, and induced apoptosis and cell cycle arrest at G1 phase in these cells.
Dual PI3K/HDAC inhibition via BEBT-908 is superior to the inhibition of PI3K or HDAC alone.
